NCT05492123 2024-01-05
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer
Hospital Israelita Albert Einstein
Phase 2 Recruiting
Clinical Trials
4 trialsNCT05504642 2023-04-18
CERAD-IMMUNE
Universitätsklinikum Köln
Phase 2 Withdrawn
NCT01693783 2022-11-08
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn